The Hematologic Malignancy Center at Dana-Farber/Boston Children's is one of the top centers of its kind in the world. We offer specialized programs for the treatment of leukemia, lymphoma, histiocytosis, and lymphadenopathy. Our center played a key role in refining treatment for childhood leukemia, resulting in today's cure rates of more than 90 percent for pediatric acute lymphoblastic leukemia, and we continue to lead high-impact clinical trials designed to increase cure rates and decrease treatment-related toxicities for long-term survivors.
Highlights of the Hematologic Malignancy Center include:
A specialized program for patients receiving cancer treatment who have experienced a decrease or loss of reproductive function.
Providing care and advocacy for survivors of childhood cancer through ongoing education, support, and research on the long-term effects of cancer treatments.
Social workers, psychologists, and resource specialists offering help with the social, emotional, and psychological aspects of caring for children with cancer.
Phone: 617-632-5508Online form: Request an appointment
U.S. News & World Report ranked Dana-Farber/Boston Children's the #1 pediatric cancer hospital in the nation.
Sarah Levin is 11 years old and has beaten acute lymphoblastic leukemia (ALL) twice. This is her story in her own words.
Dana-Farber/Boston Children's is a teaching affiliate of Harvard Medical School.